Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Clinical outcomes, anticoagulation practice patterns, and quality of life after cancer-associated pulmonary embolism: secondary outcomes of the Hydra randomized clinical trial.

Created on 15 Nov 2026

Authors

Bram Akerboom, Emily S L Martens, Britta Buechler, Luca Valerio, Stavros Konstantinides, Michiel Coppens, Francis Couturaud, Yordi P A van Dooren, Marco J J H Grootenboers, René van der Griend, David Jiménez, Jenneke Leentjens, Roberto Pola, Rosa Talerico, Tobias Tritschler, Hugo Ten Cate, Karly Hamulýak, Thijs E van Mens, Frederikus A Klok, Menno V Huisman

Published in

Research and practice in thrombosis and haemostasis. Volume 10. Issue 7. Pages 107018. Epub Oct 13, 2026.

Abstract

Despite its high prevalence, practice-based data on management and outcomes after cancer-associated pulmonary embolism (PE) are scarce, and no studies have investigated quality of life.
We aimed to evaluate clinical outcomes, anticoagulation practice patterns, and quality of life after cancer-associated PE.
The Hydra randomized clinical trial assessed the safety of the YEARS algorithm versus computed tomography pulmonary angiography only to exclude acute PE in patients with cancer. Patients with PE at baseline or during 90-day follow-up were included in this study. Outcomes were recurrent venous thromboembolism, major bleeding, all-cause mortality, anticoagulation practice patterns, and quality of life as assessed by the Pulmonary Embolism Quality of Life (PEmb-QoL) questionnaire. PEmb-QoL scores were compared with those for the general PE population reported in the FOCUS study. Lower scores indicate better QoL.
A total of 125 patients were included, of which 103 (82%) had PE at baseline, and 22 (18%) developed PE during follow-up. The 90-day cumulative incidence of recurrent venous thromboembolism and major bleeding was 2.5% (95% CI 0.67%-6.6%) and 2.5% (95% CI 0.68%-6.7%), respectively. All-cause mortality at 90 days was 32% (95% CI 23%-40%). Two-thirds of patients continued anticoagulation until less than 24 hours before death, and the median time between stopping anticoagulation and death was 10 days (IQR, 4-14). The median 90-day PEmb-QoL score was 33% (IQR, 13-51) versus 20% (IQR, 10-40) reported in the FOCUS study.
Patients with cancer-associated PE suffer from high mortality, high morbidity, and impaired quality of life. Anticoagulation therapy is frequently continued until the last days of life.

PMID:
43032401
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement